Skip to main content
    • Aa
    • Aa

Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer

  • S. R. D. Johnston (a1)
  • DOI:
  • Published online: 01 June 2007

Therapies that target cancers according to their characteristics (estrogen receptor +ve or –ve, for example) have been a major development in treating cancers successfully and have led to an increase in survival rates. These successes have led to increased research into even more tightly focused therapies. But targeted therapies do not work for everyone, raising issues of (1) identifying patients and (2) developing therapies that reflect our increasing understanding of the complex and differentiated traits of tumors. New targeted therapies such as small molecule signal transduction inhibitors and monoclonal antibodies are being developed to address tumors at all stages of the cell proliferation cycle and it is hoped that they may eventually transform cancer into a fully treatable condition.

Corresponding author
Correspondence to: Dr Stephen R. D. Johnston, MA, FRCP, PhD, Consultant Medical Oncologist, Department of Medicine, Royal Marsden Hospital, Fulham Road, Chelsea, London SW3 6JJ, UK. E-mail:; Tel: +44 207 808 2748; Fax: +44 207 808 2563
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.NL Spector , W Xia , H Burris 3rd, . Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 25022512.

2.DJ Slamon , B Leyland-Jones , S Shak , . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001; 344: 783792.

4.JG Paez , PA Janne , JC Lee , . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 14971500.

5.K Yu , L Toral-Barza , C Discafani , . mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249258.

7.SRD Johnston . Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in Breast Cancer. Clin Cancer Res 2006; 12: 1061s1068s.

8.RI Nicholson , RA McClelland , JF Robertson , . Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6: 373387.

9.KD Miller , LI Chap , FA Holmes , . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792799.

10.CE Geyer , J Forster , D Lindquist , . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355 (26): 27332743.

11.S Braun , K Pantel , P Muller , . Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525533.

13.V Bozionellou , D Mavroudis , M Perraki , . Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004; 10: 81858194.

14.EH Romond , EA Perez , J Bryant , . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 16731684.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Breast Cancer Online
  • ISSN: -
  • EISSN: 1470-9031
  • URL: /core/journals/breast-cancer-online
Please enter your name
Please enter a valid email address
Who would you like to send this to? *